Jeffrey Sirek - Icad Chief Officer
| ICAD Stock | USD 1.54 0.01 0.65% |
Insider
Jeffrey Sirek is Chief Officer of icad inc
| Address | 98 Spit Brook Road, Nashua, NH, United States, 03062 |
| Phone | 603 882 5200 |
| Web | https://www.icadmed.com |
Icad Management Efficiency
The company has return on total asset (ROA) of (0.0767) % which means that it has lost $0.0767 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1486) %, meaning that it created substantial loss on money invested by shareholders. Icad's management efficiency ratios could be used to measure how well Icad manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.15. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Icad's Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 891.5 K, whereas Intangible Assets are forecasted to decline to about 140.6 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeremy Hayden | Sight Sciences | 54 | |
| Robert Carlson | Biomerica | N/A | |
| Ed Joyce | Axogen Inc | N/A | |
| Benedict MD | enVVeno Medical Corp | 67 | |
| Warren Hancock | enVVeno Medical Corp | N/A | |
| Gregory Davault | Axogen Inc | 56 | |
| Michael Carter | Nevro Corp | 52 | |
| Craig Glynn | enVVeno Medical Corp | 63 | |
| Hans Boehringer | Biomerica | N/A | |
| MBA BS | Sight Sciences | N/A | |
| Jeffrey Bettinger | Establishment Labs Holdings | N/A | |
| John Ordway | Sight Sciences | N/A | |
| Robert Moccia | STRATA Skin Sciences | 65 | |
| B Johnson | Paragon 28 | 68 | |
| Paul Verrastro | CVRx Inc | 61 | |
| David MD | Sight Sciences | 54 | |
| Matt Jarboe | Paragon 28 | N/A | |
| Meghan Scanlon | Paragon 28 | 48 | |
| Rajbir Denhoy | Establishment Labs Holdings | 53 | |
| Michael Mydra | Profound Medical Corp | N/A | |
| Steven Sloan | Biomerica | 54 | |
Management Performance
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0767 |
icad inc Leadership Team
Elected by the shareholders, the Icad's board of directors comprises two types of representatives: Icad inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Icad. The board's role is to monitor Icad's management team and ensure that shareholders' interests are well served. Icad's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Icad's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dana Brown, CEO President | ||
| Eric Lonnqvist, Chief Officer | ||
| Annette Heroux, Vice Administration | ||
| Stephen Sarno, Interim Officer | ||
| Michelle Strong, Chief Officer | ||
| Jonathan Go, Sr. VP of RandD | ||
| Brian Testa, Chief Officer | ||
| Michael Klein, Ex Director | ||
| Stacey Stevens, Sr. VP of Marketing and Strategy | ||
| Jeffrey Sirek, Chief Officer | ||
| Vasu Avadhanula, Chief Officer | ||
| Bill Keyes, Senior Operations | ||
| Anthony Takazawa, Director Relations | ||
| Peter Graham, Senior Sales |
Icad Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Icad a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.0767 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 22.34 M | ||||
| Shares Outstanding | 26.35 M | ||||
| Shares Owned By Insiders | 5.63 % | ||||
| Shares Owned By Institutions | 27.15 % | ||||
| Number Of Shares Shorted | 249.09 K | ||||
| Price To Earning | (8.32) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether icad inc is a strong investment it is important to analyze Icad's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Icad's future performance. For an informed investment choice regarding Icad Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in icad inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icad. If investors know Icad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.20) | Revenue Per Share 0.718 | Quarterly Revenue Growth 0.206 | Return On Assets (0.08) | Return On Equity (0.15) |
The market value of icad inc is measured differently than its book value, which is the value of Icad that is recorded on the company's balance sheet. Investors also form their own opinion of Icad's value that differs from its market value or its book value, called intrinsic value, which is Icad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icad's market value can be influenced by many factors that don't directly affect Icad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.